Science and technology company Danaher Corporation (NYSE:DHR) revealed on Friday the launch of a definitive agreement to acquire Integrated DNA Technologies (IDT) for an undisclosed amount.
Founded by Joseph Walder, MD, PhD, IDT develops, manufactures and markets nucleic acid products for the life sciences industry in academic research, biotechnology, agriculture, medical diagnostics and pharmaceutical development. Its primary business is the manufacturing of high-quality, custom DNA and RNA oligonucleotides and has more than 1,200 employees and over 100,000 customers worldwide.
Upon closing, IDT will operate as a standalone operating company and brand within Danaher's Life Sciences platform.
The transaction, which is expected to close mid-year 2018, is subject to customary closing conditions and regulatory approvals.
THX Pharma secures European patent for Batten-1 in juvenile Batten disease
Orphalan commences Phase 3 study of trientine therapy in Wilson disease
ZAGENO named Frost & Sullivan's 2026 North American Life Sciences E-Commerce Company of the Year
Pharvaris reports Phase 3 success for deucrictibant XR in HAE prophylaxis
Sky Labs presents clinical research outcomes for ring-type blood pressure monitor CART
Etcamah–CDK4/6 inhibitor combination approved in US for ESR1-mutated HR-positive breast cancer
Ionis partner Novartis reports pelacarsen Phase 3 trial misses primary endpoint
Guardant Health wins FDA approval for Guardant360 CDx in advanced breast cancer
4basebio announces expansion of DNA offering for personalised mRNA medicines
Rznomics reports advances in high-efficiency circRNA production in Nucleic Acids Research
Kali Therapeutics' KT501 Investigational New Drug application cleared by US FDA
Thryv Therapeutics licenses new class of SGK1 inhibitors, expanding into neurodegenerative disease